# Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

- **DOI:** [10.1016/s0140-6736(26)01861-1](https://doi.org/10.1016/s0140-6736(26)01861-1)
- **Rating:** Strong (4.2 out of 5)
- **Verdict:** Retatrutide delivers substantial 80-week weight and glycaemic benefits versus placebo in obesity with type 2 diabetes, but comparative superiority remains untested.
- **Framework version:** v5.13
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-22
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fs0140-6736(26)01861-1

## Key claims

1. In adults with obesity and type 2 diabetes, once-weekly retatrutide over 80 weeks produced weight reduction of up to 18·8% from baseline with an estimated treatment difference of -13·8% versus placebo
   - Support: Well-supported
   - Type: Primary finding
   - Basis: large randomised placebo comparison with precise estimates and multiplicity-controlled testing
   - Location: Conclusion; Results; Table 2
2. The mean change from baseline in HbA1c at Week 80 was −1·38% (SE 0·06), −1·50% (0·07), and −1·45% (0·07) with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with −0·45% (0·08) for placebo.
   - Support: Well-supported
   - Type: Secondary
   - Basis: prespecified glycaemic endpoint supported by precise randomised comparisons and multiplicity-controlled testing
   - Location: Results, HbA1c; Table 2
3. [Weight reduction reached] up to 21·9% in participants with baseline BMI ≥35 kg/m²
   - Support: Well-supported
   - Type: Secondary
   - Basis: prespecified multiplicity-controlled subgroup estimate without implying a treatment-by-BMI interaction
   - Location: Discussion; Results; Table 2
4. The safety profile was generally similar to other GLP-1 and GIP/GLP-1 receptor agonists, with the most commonly reported adverse events being gastrointestinal events with retatrutide treatment.
   - Support: Tentative
   - Type: Secondary
   - Basis: indirect comparisons without active controls and exploratory safety analyses limit conclusions about similarity
   - Location: Research in Context; Table 3
5. Treatment with retatrutide resulted in significant body weight reductions beyond those previously observed in this population with GLP-1 and GIP/GLP-1 receptor agonists.
   - Support: Tentative
   - Type: Secondary
   - Basis: placebo-controlled design cannot identify comparative efficacy against active drugs across different trial populations
   - Location: Research in Context, Added value of this study

## Strengths

- **Precise evidence for sustained weight reduction** At 80 weeks, retatrutide 12 mg produced an estimated 18.8% weight reduction versus 5.1% with placebo, with a placebo-adjusted difference of −13.8 percentage points. HbA1c also improved across all retatrutide doses.
  - Dimension: contribution
  - Location: Results; Table 2
- **Randomised design with explicit analytical safeguards** Central stratified randomisation and double masking are paired with randomised-population analyses, two prespecified estimands and multiplicity control for primary and key secondary endpoints.
  - Dimension: methodological rigour
  - Location: Methods, Randomisation and masking and Statistical analysis; Tables 1–2
- **Systematic collection and reporting of harms** Safety reporting includes discontinuations, deaths and prespecified events of interest, with independent adjudication of cardiovascular, pancreatic and neurological events. Gastrointestinal events, dysesthesia and hypotension are explicitly reported.
  - Dimension: methodological rigour
  - Location: Methods, Outcomes; Results, safety; Table 3

## Limitations

- **Active drug superiority remains an indirect inference** The placebo-controlled trial cannot establish superiority to other obesity medications despite wording about reductions beyond those previously observed. One contextual benchmark also relies on unpublished TRIUMPH-1 data.
  - Dimension: positioning
  - Location: Research in Context, Added value; Discussion; References, item 13
- **Missing outcome assumptions remain clinically relevant** Treatment discontinuation ranged from 10% to 21% across arms. Multiple imputation addresses missing outcomes, but the main text does not state the proportion of Week-80 measurements observed rather than imputed.
  - Dimension: methodological rigour
  - Location: Methods, Statistical analysis; Results, participant disposition
- **Broader benefit and safety claims need qualification** Quality-of-life language extends beyond the principal controlled physical-function comparison, while other risk-factor findings are not uniformly established across doses. Exploratory safety analyses do not settle rare or longer-term harms.
  - Dimension: reporting
  - Location: Methods, Outcomes and Statistical analysis; Conclusion; Tables 2–3

## Reliability checks

No concerns (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Clean. Ethics approval, consent, registration, sponsor involvement and conflicts of interest are declared, with conditional participant-data access described. External verification of the unpublished comparator study is an assessability gap rather than a conduct finding.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Noted. 18 of 21 checkable references verified
  - 22 references in manuscript
  - 1 are books, websites or datasets — counted, but not index-checkable
  - Could not be verified automatically — queued for manual review:
    - Jastreboff Ania M, Kaplan Lee M, Frías Juan P, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 2023; 389(6): 514-26. (Crossref bibliographic search unavailable (search could not be performed) — no conclusion drawn about this reference)
    - Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023; 402(10402): 613-26. (Ambiguous: title ratio 0.61 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
    - Wharton S, Aronne Louis J, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine 2025; 393(18): 1796-806. (Crossref bibliographic search unavailable (search could not be performed) — no conclusion drawn about this reference)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-22
